Axcess Global Sciences LLC Patent - Ketone Bodies and Amino Acid Compositions
Summary
The USPTO granted patent US12599579B2 to Axcess Global Sciences LLC covering compositions of ketone bodies or ketone body precursors complexed with amino acids. The patent, effective April 14, 2026, contains 22 claims and names Gary Millet, Ryan Lowery, Jacob Wilson, and Terry Lacore as inventors. The compositions are directed toward uses including weight loss, blood glucose management, muscle performance, metabolic repair, neurological treatment, and anti-aging applications.
What changed
USPTO granted patent US12599579B2 to Axcess Global Sciences LLC for compositions combining ketone bodies or ketone body precursors with one or more amino acids. The patent application was filed July 7, 2025, under application number 19261853.
For pharmaceutical manufacturers and biotech companies developing ketone-based therapeutics or nutritional supplements, this patent establishes intellectual property protection for the claimed compositions and their specified uses including weight management, diabetes treatment, neurological disorders, and metabolic repair. Competitors seeking to develop similar products would need to design around this patent or seek licensing from the assignee.
Archived snapshot
Apr 17, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
Grant US12599579B2 Kind: B2 Apr 14, 2026
Assignee
AXCESS GLOBAL SCIENCES, LLC
Inventors
Gary Millet, Ryan Lowery, Jacob Wilson, Terry Lacore
Abstract
Compositions and methods for administering ketone bodies to a subject include a ketone body or ketone body precursor complexed with or coupled to at least one amino acid. The compositions and methods cause one or more of: weight loss, weight maintenance, reduced blood glucose level, maintenance of blood glucose level, increased muscle and physical performance, enhanced metabolic and cellular repair, improved detoxification and gut health, targeted bioavailability, sustained release and controlled absorption, increased metabolic efficiency, enhanced cellular uptake, minimized side effects, multifunctional therapeutics, improved focus, improved energy, improved cognitive function, improved mental acuity, treatment of traumatic brain injury, treatment of diabetes, treatment of neurological disorder, treatment of cancer, treatment of inflammatory condition, appetite suppression, anti-aging effects, anti-glycation effects, treatment of epilepsy, treatment of depression, improved performance, improved muscle mass, improved motor function, increased strength, increased metabolism, increased fat loss, increased fat oxidation, improved body composition, and improved mood.
CPC Classifications
A61K 31/19
Filing Date
2025-07-07
Application No.
19261853
Claims
22
Related changes
Get daily alerts for USPTO Patent Grants - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.